Genetic immunization against cervical carcinoma
US7198792B2 · kind B2 · utility
8Cited by
7References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 4, 2003 |
| Grant date | Apr 3, 2007 |
| Priority date | — |
| Expiry date | Oct 11, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An alphavirus vector system comprising nucleic acid of a human papilloma virus origin is disclosed. A method of treating or preventing cervical cancer is also disclosed. The method includes administering the alphavirus vector system and/or a cell comprising nucleic acid derived from human papilloma virus (HPV) to a subject. The alphavirus vector system or the cell may be administered as a vaccine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.